Strategic Anti-SARS-CoV-2 Serology Testing in a Low Prevalence Setting: The COVID-19 Contact (CoCo) Study in Healthcare Professionals.
dc.contributor.author | Behrens, Georg M N | |
dc.contributor.author | Cossmann, Anne | |
dc.contributor.author | Stankov, Metodi V | |
dc.contributor.author | Schulte, Bianca | |
dc.contributor.author | Streeck, Hendrik | |
dc.contributor.author | Förster, Reinhold | |
dc.contributor.author | Bosnjak, Berislav | |
dc.contributor.author | Willenzon, Stefanie | |
dc.contributor.author | Boeck, Anna-Lena | |
dc.contributor.author | Thu Tran, Anh | |
dc.contributor.author | Thiele, Thea | |
dc.contributor.author | Graalmann, Theresa | |
dc.contributor.author | Kayser, Moritz Z | |
dc.contributor.author | Zychlinsky Scharff, Anna | |
dc.contributor.author | Dopfer, Christian | |
dc.contributor.author | Horke, Alexander | |
dc.contributor.author | Pink, Isabell | |
dc.contributor.author | Witte, Torsten | |
dc.contributor.author | Wetzke, Martin | |
dc.contributor.author | Ernst, Diana | |
dc.contributor.author | Jablonka, Alexandra | |
dc.contributor.author | Happle, Christine | |
dc.date.accessioned | 2020-09-24T14:13:42Z | |
dc.date.available | 2020-09-24T14:13:42Z | |
dc.date.issued | 2020-09-04 | |
dc.identifier.citation | nfect Dis Ther. 2020 Sep 4:1–13. doi: 10.1007/s40121-020-00334-1. Epub ahead of print. PMID: 32886335. | en_US |
dc.identifier.issn | 2193-8229 | |
dc.identifier.pmid | 32886335 | |
dc.identifier.doi | 10.1007/s40121-020-00334-1 | |
dc.identifier.uri | http://hdl.handle.net/10033/622458 | |
dc.description.abstract | Background: Serology testing is explored for epidemiological research and to inform individuals after suspected infection. During the coronavirus disease 2019 (COVID-19) pandemic, frontline healthcare professionals (HCP) may be at particular risk for infection. No longitudinal data on functional seroconversion in HCP in regions with low COVID-19 prevalence and low pre-test probability exist. Methods: In a large German university hospital, we performed weekly questionnaire assessments and anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunoglobulin G (IgG) measurements with various commercial tests, a novel surrogate virus neutralisation test, and a neutralisation assay using live SARS-CoV-2. Results: From baseline to week 6, 1080 screening measurements for anti-SARS CoV-2 (S1) IgG from 217 frontline HCP (65% female) were performed. Overall, 75.6% of HCP reported at least one symptom of respiratory infection. Self-perceived infection probability declined over time (from mean 20.1% at baseline to 12.4% in week 6, p < 0.001). In sera of convalescent patients with PCR-confirmed COVID-19, we measured high anti-SARS-CoV-2 IgG levels, obtained highly concordant results from enzyme-linked immunosorbent assays (ELISA) using e.g. the spike 1 (S1) protein domain and the nucleocapsid protein (NCP) as targets, and confirmed antiviral neutralisation. However, in HCP the cumulative incidence for anti-SARS-CoV-2 (S1) IgG was 1.86% for positive and 0.93% for equivocal positive results over the study period of 6 weeks. Except for one HCP, none of the eight initial positive results were confirmed by alternative serology tests or showed in vitro neutralisation against live SARS-CoV-2. The only true seroconversion occurred without symptoms and mounted strong functional humoral immunity. Thus, the confirmed cumulative incidence for neutralizing anti-SARS-CoV-2 IgG was 0.47%. Conclusion: When assessing anti-SARS-CoV-2 immune status in individuals with low pre-test probability, we suggest confirming positive results from single measurements by alternative serology tests or functional assays. Our data highlight the need for a methodical serology screening approach in regions with low SARS-CoV-2 infection rates. | en_US |
dc.language.iso | en | en_US |
dc.publisher | Springer Healthcare | en_US |
dc.rights | Attribution-NonCommercial-ShareAlike 4.0 International | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-sa/4.0/ | * |
dc.subject | COVID-19 | en_US |
dc.subject | Coronavirus | en_US |
dc.subject | Healthcare professionals | en_US |
dc.subject | Humoral immunity | en_US |
dc.subject | Infection | en_US |
dc.subject | Pandemic | en_US |
dc.subject | SARS-CoV-2 | en_US |
dc.subject | Serological testing | en_US |
dc.subject | Virus | en_US |
dc.title | Strategic Anti-SARS-CoV-2 Serology Testing in a Low Prevalence Setting: The COVID-19 Contact (CoCo) Study in Healthcare Professionals. | en_US |
dc.type | Article | en_US |
dc.contributor.department | TWINCORE, Zentrum für experimentelle und klinische Infektionsforschung GmbH,Feodor-Lynen Str. 7, 30625 Hannover, Germany. | en_US |
dc.identifier.journal | Infectious diseases and therapy | en_US |
refterms.dateFOA | 2020-09-24T14:13:43Z | |
dc.source.journaltitle | Infectious diseases and therapy | |
dc.source.country | New Zealand |